From the above link: "Used to treat breast, lung, prostate, stomach and head/neck cancers, docetaxel generates roughly $2 billion/year for Sanofi-Aventis."
($2 billion is 17 times SNTA's market cap, BTW.)
From SNTA's 8/24/10 press release: “The combination of STA-9090 and docetaxel could possibly expand the therapeutic potential of both agents.”
I'm not close to being a biotech expert, but it sounds like SNTA's HSP-9090 may not only save Sanofi-Aventis's docetaxel from going off-patent in a few years, but more importantly, create a much improved combination drug.
Of course this is just one of many opportunities for STA-9090 -- doktorr_demento's recent 5-star post discusses many more.